Transgene expression from helper-dependent adenoviral (HD-Ad) vectors is effective and long lasting, but not permanent. Their use is also limited by the host response against capsid proteins that precludes successful gene expression upon readministration. In this report, we test the hypothesis that PEGylation of HD-Ad reduces its toxicity and promotes transgene expression upon readministration. PEGylation did not compromise transduction efficiency in vitro and in vivo and reduced peak serum IL-6 levels two-fold. IL-12 and TNF-a levels were reduced three-and sevenfold, respectively. Thrombocytopenia was not detected in mice treated with the PEGylated vector. 
Introduction
Adenoviruses are undoubtedly one of the most extensively studied viruses currently utilized for gene therapy and vaccine applications. Since the initial isolation of adenoviruses, knowledge of the viral genome increased dramatically due to interest in adenovirus as a model system for the study of eukaryotic gene expression. 1 This knowledge has translated into the development of first generation recombinant adenoviral (FG-Ad) vectors in which the E1 and E3 regions are removed and replaced by the expression cassette of the transgene of interest. Several landmark studies in the early 1990s in which FGAd vectors induced hepatocytes to rapidly produce large amounts of therapeutic proteins suggested that these vectors were viable candidates for liver directed gene transfer. 2, 3 Subsequent studies have shown that moderate doses of these vectors are capable of transducing 90% of all hepatocytes when given by intravenous injection 4, 5 and further suggest that FG-Ad vectors are ideal candidates for treatment of diseases such as cardiovascular and metabolic disorders where high levels of transgene expression are necessary.
FG-Ad, however, has fallen short of the 'ideal' gene therapy vector due to acute toxicity, transient gene expression in vivo and limited transgene expression after readministration. These effects arise from the inherent ability of the virus to elicit a strong immune response in an immunocompetent host. The host response to adenovirus occurs in three phases in animal models and humans. 6 The first phase occurs as early as 1 h after systemic administration of the virus and continues for 4 days. This acute phase is characterized by thrombocytopenia, intense periportal polymorphonuclear leukocyte infiltration, and elevated liver enzymes. 4, 7 These effects are largely due to activation of Kupffer cells, which produce and release several cytokines (IL-1, IL-6, TNF-a) and chemokines (MIP-2, MCP-1, IP-10 and RANTES) into the general circulation for the recruitment of inflammatory cells. 8, 9 Macrophages and dendritic cells in the spleen and peritoneum also release chemokines and cytokines into the circulation, contributing to neutrophil-dependent hepatic injury and progression toward the second phase of the inflammatory process. 10 A large body of evidence suggests that virus capsid proteins alone are responsible for induction of the acute phase of the immune response. 11 The second phase of the immune response begins 5-7 days after administration of vector and is directed against newly transduced cells. Adenovirusspecific major histocompatibility complex (MHC) class I-restricted CD8 + T cells directed against cells expressing viral genes and transgene products are generated. 12, 13 MHC class II helper CD4 + T cells, largely stimulated by the presence of adenovirus capsid proteins, are also generated.
14 Removal of transduced cells by activated lymphocytes significantly limits the duration of transgene expression in the immunocompetent host and is responsible for inducing a self-limited inflammation in the liver. 5, 8 At high viral loads, this can progress to severe and lethal liver necrosis, disseminated intravascular coagulopathy, bleeding and, in a few cases, a systemic inflammatory response syndrome, a condition characterized by multiorgan failure, sepsis and severe trauma. 4, 7, 15, 16 The chronic host response continues for several weeks to several months after FG-Ad administration. During this time, cells initially expressing low levels of viral genes and transgene products are recognized and eliminated by cytotoxic T cells. 13 In addition, CD4 + T-cell-dependent humoral immunity is responsible for the production of antiadenoviral neutralizing antibodies, which rapidly clear the virus from the circulation and prevent successful gene transfer upon readministration. 17 In an effort to minimize the immune response and associated toxicity of FG-Ad vectors, helper-dependent adenoviral (HD-Ad) vectors in which all the elements of the viral genome except the inverted terminal repeats (ITRs) and packaging signal (C) are removed were developed. 18 In immunocompetent animal models, HDAd vectors exhibit levels of gene expression that are comparable if not superior to FG-Ad vectors with a significant reduction in toxicity. 19, 20 Unlike FG-Ad vectors, stable, long-term (41 year) gene expression has been reported in several animal models after a single dose of HD-Ad. [20] [21] [22] This represents a significant advance in the area of adenovirus-mediated gene delivery.
Even though HD-Ad vectors have been proven to be superior to FG-Ad vectors with respect to long-term gene expression and toxicity profile, their use is limited by the innate immune response against virus capsid proteins. It has recently been shown that HD-Ad vectors, when given systemically, demonstrate a nonlinear dose response similar to that of FG-Ad, suggesting that they are sequestered by Kupffer cells. 23 This interaction precipitates the acute phase of the innate immune response as animals treated with HD-Ad exhibit similar cytokine secretion patterns and toxicity profiles including coagulopathy and multiorgan failure as those described in animals treated with comparable doses of FG-Ad. 24, 25 In addition, neutralizing antibodies against the viral capsid are produced, preventing successful readministration of HD-Ad vectors of the same serotype. 26 Thus, interaction of vector capsid proteins with the innate immune system is, at the moment, the final obstacle that must be overcome in the host with respect to the development of nonimmunogenic adenoviral vectors.
Conjugation of activated monomethoxypoly(ethylene) glycol to the capsid proteins of FG-Ad vectors (PEGylation) significantly reduces activation of cytotoxic T lymphocytes and production of neutralizing antibodies against native capsid proteins without compromising transduction efficiency in vivo. 27, 28 PEGylated vectors can also produce significant transgene expression in animals immunized with unmodified virus. Preliminary studies suggest that PEGylation significantly reduces cytokine secretion profiles and the toxicity associated with the acute phase of the immune response against an FG-Ad vector. In this report, we test the hypothesis that PEGylation of a HD-Ad vector will dampen the innate immune response against capsid proteins and eliminate any remaining toxicity associated with systemic administration of the virus.
Results

Physical characterization of PEGylated HD-Ad vectors
Based upon previous experience with PEGylation of recombinant viral vectors, a 1 h reaction time was selected. 27, 28 Four separate lots of HD-Ad were employed in the studies outlined below. The average titer of all HD-Ad preparations prior to PEGylation was 1.96 Â 10 9 70.27 lac-forming units (lfu)/ml. PEGylated preparations had an average titer of 8.75 Â 10 8 70.56 lfu/ ml after conjugation. This was not significantly different from the titer of sham treated virus processed in the same manner as the modified virus in the absence of PEG (8.41 Â 10 8 70.78 lfu/ml, P ¼ 0.001), which suggests that the drop in titer was due to reaction conditions and not the PEGylation process itself.
Changes in the surface properties of the virus capsid during PEGylation were monitored by several biophysical tests. When the conjugation reaction was complete, the average PEG-Dextran partition coefficient shifted from 0.870.03 to 1.170.08, suggesting that vectorsolvent interactions were significantly altered. The PEGylation reaction was also monitored by capillary electrophoresis. Unmodified HD-Ad had a major peak at 2.8 min (Peak C, Figure 1 ). The PEG-HD-Ad vector was detected as a single peak at 1.8 min (Peak B). A standard solution of free PEG produced a single peak at 0.5 min (Peak A) and was absent from the PEGylated preparation, indicating that free PEG was efficiently removed after the conjugation reaction. This was also confirmed by a spectrophotometric assay designed to quantitate polyethylene glycol in protein preparations. 29 An in vitro neutralization protection assay was used to confirm that PEGylation could effectively shield the HDAd vector from antibody-mediated neutralization prior to use in vivo. Virus was added to 293 cells in the presence of mouse serum containing antibodies against the unmodified vector. Transduction levels were compared to that of the same vector in the presence of nonimmune serum, which was considered to be 100%. A 1:20 dilution of immune serum, sufficient to reduce the transduction efficiency of the unmodified virus by 93%, compromised the infectivity of the PEGylated vector by only 23% (Figure 2 ). Transduction efficiency of the PEGylated vector was reduced by 16% in the presence of immune serum at a 1:200 dilution, which reduced the infectivity of the unmodified virus by 79%. The transduction efficiency of the PEGylated vector was unaffected by the 1:2000 dilution of immune serum that reduced the infectivity of the unmodified virus by 62%.
To estimate the number of PEG molecules associated with each virus particle in a given preparation and to assess the reproducibility of the PEGylation process, an aliquot of each lot of HD-Ad was reacted with biotinylated monomethoxypoly(ethylene) glycol activated by succinimidyl succinate under the same condiBiology of PEGylated HD-adenovirus MA Croyle et al tions as the modified and sham treated control preparations. Unreacted PEG was removed from these preparations by dialysis at 41C overnight. Using PEG-biotin as a reference standard in an enzyme-linked immunosorbent assay (ELISA) assay, we found that the average number of PEG molecules associated with each virus particle in the studies outlined here was 10 5377405.
In vivo performance of PEGylated HD-Ad
The in vivo transduction efficiency of both native and conjugated vectors was tested by injecting groups of five male C57BL/6 mice via the tail vein with 1 Â 10 11 viral particles of either unmodified or PEGylated HDAd-SRa-bGEO. Control mice were treated with 100 ml of potassium phosphate-buffered saline. After 7 days, mice were euthanized, necropsied and transgene expression assessed by ELISA and histochemical staining.
27
Tissues from animals treated with the native virus contained 1.370.8 Â 10 6 pg of beta-galactosidase/mg homogenate protein (HD naïve, Figure 3 5 lfu/ml were incubated in the presence of heat-inactivated immune serum from C57BL/6 mice for 30 min prior to addition to 293 cell monolayers. Percent transduction is the ratio of the number of positive cells from virus incubated in immune serum to the number of cells transduced by virus incubated in the presence of nonimmune serum. At each concentration of immune serum, the transduction efficiency of the PEGylated virus was significantly higher than that of the native virus. Data reflect the results from triplicate samples from four separate lots of virus. *Po0.05; **Po0.001 Figure 1 Representative capillary electropherograms of (a) monomethoxypoly(ethylene) glycol activated by succinimidyl succinate (10 mg/ml), (b) PEGylated HD-Ad-SRa-bGEO, and (c) unmodified HD-Ad-SRa-bGEO. Samples were diluted 1:2 with sample buffer (20 mM sodium phosphate buffer, pH 7.0, 5 mM sodium chloride). Capillary length was 27 cm. Virus was detected at 214 nm. AU, absorbance units. Figure 3 PEGylation does not compromise the transduction efficiency of helper-dependent adenovirus and allows for significant levels of gene expression in immunized mice. All mice were dosed with 1 Â 10 11 viral particles of recombinant virus and euthanized 7 days after administration (or rechallenge) for analysis of beta-galactosidase transgene expression. Even though similar levels of transgene expression were found in the liver of naïve animals treated with unmodified (HD) or PEGylated HD-AdSRa-bGEO (PEG-HD), significant transgene expression could only be detected in animals rechallenged with PEGylated HD-Ad-SRa-bGEO (HD/PEG-HD) after prior immunization with unmodified HD-Ad-STK109 (P ¼ 0.0001). The beta-galactosidase transgene could not be detected in samples from mice immunized and rechallenged with unmodified vectors (HD/HD). Data reflect average values7s.e.m. for five mice from each treatment group.
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Vector readministration
In total, 15 C57BL/6 mice were treated with 1 Â 10 11 viral particles of unmodified HD-Ad-STK109 by tail vein injection. At 28 days after immunization, blood was collected from the retro-orbital plexus and assessed for antiadenovirus antibody and serum hA1AT. Animals selected for rechallenge with 1 Â 10 11 viral particles of either PEGylated or unmodified HD-Ad-SRa-bGEO had an average antiadenovirus neutralizing antibody titer of 3047140.1 reciprocal dilution and hA1AT levels of 177.07772.8 mg/ml. Mice were killed 7 days after rechallenge. Tissue homogenates from animals rechallenged with the PEGylated virus contained 5.170.4 Â 10 5 pg of beta-galactosidase/mg protein (HD/HD-PEG, Figure 3 ). This was significantly higher than what was observed in homogenates from animals rechallenged with the unmodified virus (52.2719.2 pg/mg protein, HD/HD, Figure 3 , P ¼ 0.0001). Tissue sections from animals rechallenged with the PEGylated vector revealed that approximately 60% of the hepatocytes were transduced by the PEGylated virus (Figure 4e ). Beta-galactosidase could not be detected in liver sections from mice rechallenged with the unmodified virus (Figure 4d ).
Toxicity profiles of PEGylated HD-Ad
In a separate series of experiments, several serum biochemical markers were measured at various times following administration of either unmodified or PEGylated HD-Ad-SRa-bGEO. As it has been suggested that the immune response against adenoviral capsid proteins are largely responsible for the toxicity associated with systemic administration these recombinant viral vectors, 30 these markers were also measured after systemic administration of unmodified and PEGylated FG-Ad expressing the beta-galactosidase transgene. In the studies described below, C57BL/6 mice were given a single intravenous dose of 8 Â 10 10 viral particles. Levels of transgene expression in the liver of animals treated with each vector 3 and 7 days after administration are summarized in Table 1 .
Pro-inflammatory cytokines
Serum samples were collected 6 h after administration of each vector and analyzed for IL-6, IL-12 and TNF-a, markers commonly associated with activation of the innate immune response against recombinant adenoviral vectors. 31 A single 6 h time point was selected because, in a mouse model, these cytokines peak approximately 6 h after vector administration and rapidly decline to baseline values by 24 h. 10 Unmodified vectors induced cytokine production in a similar manner. There was no statistical difference (P ¼ 0.06) between serum IL-6 levels of mice treated with the first generation virus (E1/E3) and HD-Ad-SRa-bGEO (HD) (1485.67539.8 and 1144.27276.9 pg/ml, respectively, Figure 5a ). PEGylation of the first generation virus (PEG-E1/E3) reduced IL-6 levels by a factor of 4 (P ¼ 0.002). Modification of HD-Ad-SRa-bGEO (PEG-HD) also significantly reduced IL-6 levels by a factor of 2 (P ¼ 0.01). Serum samples taken from mice treated with unmodified FG-Ad contained 1264.1726.7 pg/ml of IL-12 and were also not statistically different from those treated with HD-AdSRa-bGEO (1383.77333.3, P ¼ 0.08, Figure 5b ). PEGylation significantly reduced IL-12 levels of animals treated with first generation adenovirus by a factor of 3 (P ¼ 0.001). A similar drop in IL-12 was detected in animals treated with modified HD-Ad. Mice treated with native FG-Ad had an average level of 176730 pg/ml of TNF-a (Figure 5c ). Animals treated with the HD-Ad vector had an average level of 202740 pg/ml. PEG conjugation of either vector reduced TNF-a to baseline levels (22.575 pg/ml, saline treated animals). 
Serum transaminases
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were used to monitor hepatotoxicity associated with systemic administration of recombinant adenoviral vectors (Table 2) . Animals treated with unmodified FG-Ad were the only group to experience significant elevations in serum transaminase levels 3 days after administration with respect to saline controls (P ¼ 0.001). There was no significant difference between ALT and AST levels of mice treated with either unmodified or PEGylated HD-Ad at this timepoint (P ¼ 0.07). Transaminase levels from these animals also fell within the accepted normal range for C57BL/6 mice. 32 ALT and AST levels in mice treated with unmodified FG-Ad continued to be significantly elevated 7 days after administration (P ¼ 0.01 and 0.001, respectively) while levels from animals treated with either unmodified or PEGylated HD-Ad were not significantly altered.
Discussion
The method by which monomethoxypoly(ethylene) glycol activated by succinimidyl succinate was conjugated to the capsids of HD-Ad outlined here does not significantly differ from that previously optimized for FG-Ad vectors. 27, 28 Biophysical tests demonstrate that our protocol alters the surface properties of the vector but does not compromise transduction efficiency in vitro and in vivo (Figures 3 and 4, Table 1) . 27, 28 Results from the Figure 6 PEGylation of helper-dependent adenovirus prevents vectorinduced thrombocytopenia after systemic delivery. In total, 14 days prior to vector administration, baseline platelet counts were determined (t ¼ 0). Mice were dosed with either 8 Â 10 10 viral particles of unmodified (HD) or PEGylated (PEG-HD) Ad-SRa-bGEO or 100 ml of saline (PBS, vehicle control). At each timepoint, mice were terminally bled and half the blood collected in tubes treated with sodium citrate for platelet analysis. Data reflect average values7the s.e.m. for five mice from each treatment group. Biology of PEGylated HD-adenovirus MA Croyle et al PEG-Biotin assay suggest that PEG molecules occupy approximately two-thirds of available sites on our vectors. Data from the in vitro neutralizing antibody assay also suggest that the polymer does not completely blanket the virus capsid because the transduction efficiency of the modified vector was slightly compromised in the presence of anti-adenovirus antibody (Figure 2 ). Despite this, the vector was sufficiently protected from neutralization in vivo and could achieve significant gene expression upon readministration (Figures 3 and 4) .
The level of gene expression achieved with the PEGylated HD-Ad vector in animals immunized with unmodified virus is significant in the context of studies previously performed with PEGylated FG-Ad. Transgene expression from immunized mice rechallenged with a single intravenous dose of FG-Ad modified by the same PEG chemistry employed in this study was significantly higher than that of animals treated with two doses of unmodified vector, but was several logs lower than that seen from a similar dose in naïve animals. 27 It was reasoned that this reduction might be due to the immune response against viral gene products, which could not be affected by PEGylation. The data reported here suggest that this may be the case as the amount of transgene expression achieved with a PEGylated HD-Ad vector in mice immunized against Hd-Ad was not statistically different from that of naïve animals treated with a single dose of the same vector (Figure 3 ). While these results are encouraging, one must realize that the biology of PEGylated biomolecules varies greatly. In many cases, repeat administration of a PEGylated compound can induce immune tolerance to the native compound. 33, 34 In other instances, antibodies against PEGylated antigens have been detected. 35 Both of these scenarios could have deleterious effects in patient populations in the context of inducing tolerance to natural adenoviral infection or prevention of successful readministration of the PEGylated virus over time, making additional studies to characterize the immunological properties of PEGylated HD-Ad vectors warranted.
The primary goal of this study was to determine if PEGylation of an HD-Ad vector could reduce the innate response in an immunocompetent host. Recent studies have found that animals treated with HD-Ad exhibit similar cytokine secretion patterns and toxicity as those treated with comparable doses of FG-Ad during the very early acute phase of the immune response. 24, 25 We also found this to be the case in animals treated with either unmodified vector ( Figure 5 ). The fact that cytokine levels in animals treated with PEGylated FG-Ad were not statistically significant from those treated with PEGylated HD-Ad further supports the hypothesis that virus capsid proteins play a key role in triggering early innate immunity. This is not surprising since the capsid of the HD-Ad vector contains structural protein subunits provided by the helper virus, generally an FG-Ad serotype 5 vector. It is also important to note that PEGylation significantly reduced cytokine production but did not ablate it. This may be due to the fact that the polymer did not completely cover the virus capsid. It is also not clear if this reduction is sufficient to prevent progression to an acute inflammatory syndrome. 15, 36 The importance of mitigating these effects has been underscored by the death of a patient in a clinical trial after administration of a high dose of a recombinant adenoviral vector containing a functional gene for ornithine trascarbamylase. 15 Additional studies in non-human primates may provide further insight into how these vectors would perform in a clinical setting.
Other biochemical markers suggest that PEGylation may adequately dampen the innate response in a manner that reduces vector-induced tissue damage, coagulopathy and inflammation. Even though each vector produced similar levels of gene expression (Table 1) , elevated serum transaminases were only detected in animals treated with unmodified FG-Ad (Table 2) . Platelet counts of animals treated with the PEGylated vectors did not decline throughout the entire study period (Figure 6 ). Although the exact molecular mechanism of adenovirus-induced platelet clearance is not known, 37 thrombocytopenia associated with viral infec- Data represent the mean7standard error of four mice per treatment group. AST, aspartate aminotransferase; ALT, alanine aminotransferase; U/l, units per liter. Saline controls were bled 3 and 7 days after treatment in the same manner as animals dosed with virus. **P ¼ 0.001, *P ¼ 0.01. a Derived from reference 32.
Biology of PEGylated HD-adenovirus MA Croyle et al tion occurs via one of two mechanisms: increased lysis or destruction of platelets directly resulting from viral contact or destruction of virus-infected platelets by immune mechanisms. 38 Given this information, we believe that conjugation of the polymer to the virus is sufficient to prevent interaction with platelets and may prevent disseminated intravascular coagulation at vector doses necessary to achieve therapeutic levels of a given transgene.
The development of HD-Ad vectors with improved toxicity profiles and extended terms of gene expression represents a significant achievement in the area of adenovirus-mediated gene delivery. This manuscript summarizes our initial effort to determine if PEGylation, a technique initially pioneered to protect protein and peptide-based pharmaceuticals from degradation during delivery, 39 can dampen the innate immune response initiated by virus capsid proteins. Poly(ethylene) glycol has a low toxicity profile, does not have immunogenic properties and has been approved by the Food and Drug Administration (FDA) for use in foods, cosmetics and pharmaceuticals including parenteral, topical, rectal and nasal formulations. 35 35 This suggests that an optimized PEGylation process is reproducible and could be adapted to large-scale production if appropriate analytical and quality control methodologies are in place. We have found that combining PEGylation and HD-Ad technologies significantly reduces cytokine secretion, serum transaminases and alleviates vector-induced thrombocytopenia after systemic administration. While these vectors hold great promise for liver-directed gene therapy, additional studies to fully understand their biology and performance in immunocompetent hosts are necessary.
Materials and methods
Production of recombinant adenoviral vectors
Two HD-Ad vectors were used in the following studies. The first vector, HD-Ad-SRa-bGEO, contains an expression cassette for the bGEO transgene, a fusion gene between the Escherichia coli beta-galactosidase gene and the neomycin resistance gene under the control of the SRa promoter as described previously. 41 The second vector, HD-Ad-STK109, contains the complete human alpha-1-antitrypsin (hA1AT) gene sequence. 42 Rescue and amplification of the vectors were performed using the AdLC8Luc1 helper virus as described. 43, 44 A FG-Ad vector expressing E. coli beta-galactosidase under the control of a CMV promoter was amplified in 293 cells as described previously. 28 All vectors were purified from cell lysates by banding twice on cesium chloride gradients and desalted on Econo-Pac 10DG disposable chromatography columns (Bio-Rad, Hercules, CA, USA) equilibrated with 0.2 M potassium phosphate buffer (pH 7.4). Vector concentration was determined by UV spectrophotometric analysis at 260 nm and a limiting dilution assay. 45 All experiments were performed with freshly purified virus. Helper virus contamination was not detectable by Southern blot analysis (o0.2% contamination).
PEGylation of recombinant adenoviral vectors
The protein content of each viral preparation was determined with Bio-Rad DC Protein assay reagents and bovine serum albumin as a standard (Bio-Rad, Hercules, CA, USA). In total, 10 mg of monomethoxypoly(ethylene) glycol activated by succinimidyl succinate (SSPEG, mw 5000, Sigma-Aldrich, St Louis, MO, USA) was added for each microgram of protein present in each preparation. Conjugation reactions were performed as described previously at 251C with gentle agitation. 28 Reactions were stopped by addition of a 10-fold excess of L-lysine (Sigma-Aldrich) with respect to the amount of PEG added. Unreacted PEG, excess lysine, and reaction byproducts were eliminated buffer exchange over a second Econo-Pac 10DG disposable chromatography column (Bio-Rad) equilibrated with 100 mM potassium phosphate-buffered saline (pH 7.4). A separate aliquot of virus was treated and processed in the absence of SSPEG in the same manner as the conjugated virus and served as the unPEGylated control for all studies outlined below.
Characterization of PEGylated HD-Ad vectors Capillary zone electrophoresis. PEGylated and unPEGylated adenoviral vectors were characterized by capillary zone electrophoresis using a Beckman PACE 5000 system (Beckman Coulter, Fullerton, CA, USA) with an untreated 50 mm (ID) Â 27 cm capillary. The temperature of the capillary was controlled at 221C. A preliminary 2 min wash in 1 N NaOH followed by a 2-min wash in nanopure water and a third wash in running buffer (20 mM sodium phosphate, pH 7.0, 5 mM sodium chloride) were performed prior to sample analysis. A voltage of 17 kV was used for the separations and the detector signal at 214 nm was recorded and processed by the PACE station software package.
Estimation of PEG-virus ratio. A biotin-streptavidin based ELISA was used to estimate the number of PEG molecules on viral capsids as described previously. 46 For each lot of virus, a small aliquot was also conjugated to biotinylated SSPEG (mw 5000, Nektar Therapeutics, formerly Shearwater Corporation, Huntsville, AL, USA) under the conditions described above. Unreacted PEG was removed by dialysis against 100 mM potassium phosphate buffered saline (pH 7.4). Virus concentration was predetermined by limiting dilution. Samples containing specific concentrations of PEG-biotin served as standards. Virus and standards were added to a Streptawell strepavidin coated 96-well assay plate (Roche Applied Science, Indianapolis, IN, USA) for 1 h at 371C. and PEGylated viruses were determined as described previously. 28 Partitioning assays were performed in single microfuge tubes containing 1 g of a two-phase system of 4.75% (w/w) PEG 8000 (Sigma Chemicals, St Louis, MO, USA), 4.75% Dextran T500 (Amersham Biosciences, Piscataway, NJ, USA), in 0.15 M NaCl containing 0.01 M sodium phosphate buffer, pH 6.8. Viruses were incorporated into the system by replacing 0.1 g of the biphasic preparation with 0.1 g of the virus preparation. Samples were mixed 30-40 times by inversion and left to settle under gravity until separation of the phases was complete. Aliquots from the top and bottom phases were analyzed for protein concentration with Bio-Rad Protein assay reagents. The partition coefficient (K) is determined by the ratio between the protein concentrations in the top and bottom phases.
Neutralization protection assay. In order to confirm that PEGylation could effectively shield each modified HD-Ad preparation from neutralization prior to use in vivo, unmodified and PEGylated HD-Ad preparations were incubated with immune or nonimmune heat inactivated serum from C57BL/6 mice for 30 min at room temperature as described previously. 28 In total, 200 ml aliquots (equivalent to a multiplicity of infection of 50) were applied to 293 cells in triplicate. After 2 h, virus was replaced with Dulbecco's modified Eagle's medium (DMEM, Cellgro, Mediatech, Herndon, VA, USA) supplemented with 10% fetal bovine serum (FBS, Cellgro). At 24 h after infection, medium was removed, cells washed with Dulbecco's sodium phosphate-buffered saline (pH 7.4, Sigma-Aldrich, St Louis, MO, USA) and assessed for beta-galactosidase expression histochemically. Transduction levels were compared to that of the same vector in the presence of nonimmune serum, which was normalized to be 100%.
Animal studies
All procedures outlined here were approved by the Institutional Animal Care and Use Committee of The University of Texas at Austin. Male C57BL/6 (H-2 b ) mice (6-8 weeks old) were purchased from Taconic Laboratories (Germantown, NY, USA). Vectors were administered intravenously through the tail vein in 100 ml of 100 mM potassium phosphate-buffered saline (pH 7.4). Study designs and dosing schedules are detailed in the text and figure legends.
Neutralization assay. Antiadenovirus antibody titers of mice immunized with unmodified HD-Ad were determined by incubating serum samples at 561C for 30 min to inactivate complement followed by dilution in DMEM in two-fold increments starting from a 1:20 dilution as described previously. 27 Each dilution (100 ml) was mixed with an aliquot of a standard stock of unmodified adenovirus expressing E. coli beta-galactosidase (10 6 pfu), incubated for 1 h at 371C, and applied to HeLa cells in 96-well plates (2 Â 10 4 cells/well). In total, 100 ml of DMEM supplemented with 20% FBS was then added to each well. Cells were incubated at 371C for 24 h. Neutralizing antibody titers were calculated as the highest dilution at which 50% of the cells stained blue by visual inspection.
Evaluation of gene expression and toxicity. All tests were performed at The University of Texas at Austin except for serum hA1AT, which was determined at Baylor College of Medicine by an (ELISA) as described previously. 20 Beta-galactosidase levels in tissue samples were assessed by an ELISA assay and histochemical staining as described previously. 27 Serum ALT and AST levels were determined by a Vitros DTSC autoanalyzer (Ortho-Clinical Diagnostics, Rochester, NY, USA). Serum cytokines were assessed by an ELISA assay according to the manufacturer's protocol (BioSource International, Camarillo, CA, USA). Platelet counts were performed by an outside contract lab (Antech, Irvine, CA, USA).
Data analysis. SuperANOVA was used to perform a one-way analysis of variance with sp. Bonferroni/Dunn control and all means comparison post hoc analyses to determine differences between individual groups (Abacus Concepts, Berkeley, CA, USA). Differences were determined to be significant when the probability of chance explaining the results was reduced to less than 5% (Po0.05).
